Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts

Arthritis and Rheumatology

Volumn 67, Issue 10, 2015, Pages 2749-2758

  Piera Velazquez, Sonsoles ^a   Makul, Alma ^a   Jiménez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; COLLAGEN TYPE 1; FIBRONECTIN; HYDROGEN PEROXIDE; IMATINIB; MESSENGER RNA; PROTEIN KINASE C DELTA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; ROTTLERIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN; NOX4 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; WESTERN BLOTTING; CASE CONTROL STUDY; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; SKIN;

CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN; FIBROBLASTS; FIBRONECTINS; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN PEROXIDE; NADPH OXIDASE; OXIDATIVE STRESS; PROTEIN KINASE C-DELTA; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84947125109     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39242     Document Type: Article

References (49)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
2. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annual Rev Pathol 2011;6:509-37.
3. Balbir-Gurman A, Braun-Moscovici Y. Scleroderma: new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol 2012;26:13-24.
4. Assassi S, Mayes MD. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis? Curr Opin Rheumatol 2013;25:686-91.
5. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:134-44.
6. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
7. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008;34:115-43.
8. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011;8:42-54.
9. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008;34:41-55.
10. Matucci-Cerinic M. Kahaleh B, Wigley FM. Evidence that systemic sclerosis is a vascular disease [review]. Arthritis Rheum 2013;65:1953-62.
11. Altorok N, Wang Y, Kahaleh B. Endothelial dysfunction in systemic sclerosis. Curr Opin Rheumatol 2014;26:615-20.
12. Varga J, Whitfield ML. Transforming growth factor-β in systemic sclerosis (scleroderma). Front Biosci (Schol Ed) 2009;1:226-35.
13. Jimenez SA, Castro SV, Piera-Velazquez S. Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. Curr Rheumatol Rev 2010;6:283-94.
14. Lafyatis R. Transforming growth factor β - at the centre of systemic sclerosis. Nat Rev Rheumatol 2014;10:706-19.
15. Varga J, Pasche B. Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol 2008;20:720-8.
16. Rosenbloom J, Jimenez SA. Molecular ablation of transforming growth factor-β signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis [editorial]. Arthritis Rheum 2008;58:2219-24.
17. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-40.
18. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001;44:2653-64.
19. Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin Immunopathol 2008;30:329-37.
20. Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative damage in systemic sclerosis. J Rheumatol 2010;37:2540-7.
21. Shi-wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, et al. Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology (Oxford) 2012;51:2146-54.
22. Gabrielli A, Svegliati S, Moroncini G, Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J 2012;6:87-95.
23. Grygiel-Gorniak B, Puszczewicz M. Oxidative damage and antioxidative therapy in systemic sclerosis. Mediators Inflamm 2014; 2014:389582.
24. Hecker L, Cheng J, Thannickal VJ. Targeting NOX enzymes in pulmonary fibrosis. Cell Mol Life Sci 2012;69:2365-71.
25. Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999;112:78-84.
26. Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004;116:595-600.
27. Savas E, Aksoy N, Pehlivan Y, Sayiner ZA, Ozturk ZA, Tabur S, et al. Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis. Wien Klin Wochenschr 2014;126:341-6.
28. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
29. Leto TL, Morand S, Hurt D, Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antiox Redox Signal 2009;11:2607-19.
30. Montezano AC, Burger D, Ceravolo GS, Yusuf H, Montero M, Touyz RM. Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. Clin Sci (Lond) 2011;120:31-41.
31. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 2007;406:105-14.
32. Jiang F, Liu GS, Dusting GJ, Chan EC. NADPH oxidasedependent redox signaling in TGFβ-mediated fibrotic responses. Redox Biol 2014;2:267-72.
33. Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFβ1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65:733-8.
34. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-81.
35. Sancho P, Mainez J, Crosas-Molist E, Roncero C, Fernandez-Rodriguez CM, Pinedo F, et al. NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PloS One 2012;7:e45285.
36. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010; 53:7715-30.
37. Gaggini F, Laleu B, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, et al. Design synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors. Bioorg Med Chem 2011;19:6989-99.
38. Jiang JX, Chen X, Serizawa N, Szyndralewiew C, Page P, Schroder K, et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 2012;53:289-96.
39. Green DE, Murphy TC, Kang BY, Kleinhenz JM, Szyndralewiew C, Page P, et al. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol 2012;47:718-26.
40. Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 2012;56:2316-27.
41. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008;58:2854-65.
42. Jimenez SA, Gaidarova S, Saitta B, Sandorfi N, Herrich DJ, Rosenbloom JC, et al. Role of protein kinase C-d in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001;108:1395-403.
43. Hempel SL, Buettner GR, O'Malley YQ, Wessels DA, Flaherty DM. Dihydrofluorescein diacetate is superior for detecting intracellular oxidants: comparison with 20,70-dichlorodihydrofluorescein diacetate, 5(and 6)-carboxy-20,70-dichlorodihydrofluorescein diacetate, and dihydrorhodamine 123. Free Radic Biol Med 1999;27:146-59.
44. Svegliati S, Cancello R, Sambo P, Luchetti M, Paroncini P, Orlandini G, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2: amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005;280:36474-82.
45. Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, et al. Transforming growth factor-β1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Lung Cell Mol Physiol 2006;290:L661-73.
46. Boudreau HE, Casterline BW, Rada B, Korzeniowska A, Leto TL. Nox4 involvement in TGF-b and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med 2012;53:1489-99.
47. Bai G, Hock TD, Logsdon N, Zhou Y, Thannickal VJ. A farupstream AP-1/Smad binding box regulates human NOX4 promoter activation by transforming growth factor-β. Gene 2014; 540:62-7.
48. Sun X, Majumder P, Shioya H, Wu F, Kumar S, Weichselbaum R, et al. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J Biol Chem 2000;275:17237-40.
49. Spadoni T, Svegliati Baroni S, Amico D, Albani L, Moroncini G, Avvedimento EV, et al. A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol 2015;67:1611-22.